Core Viewpoint - The article emphasizes the strategic opportunities for the securities industry in China, particularly focusing on Huatai Securities' commitment to becoming a leading investment bank while supporting the modernization of the Chinese economy through innovative financial services and international expansion [1][2]. Group 1: Company Development and Strategy - Huatai Securities has evolved from a local brokerage to a leading comprehensive financial group with total assets exceeding 1 trillion yuan and client assets over 5 trillion yuan [2]. - The company aims to build a first-class investment bank driven by technological empowerment and internationalization, aligning with the goals set forth in the 14th Five-Year Plan [2][11]. - Huatai Securities has actively engaged in the development of new productive forces, focusing on strategic emerging industries and providing high-quality financial services to technology-driven enterprises [4][11]. Group 2: Wealth Management and Client Services - The company recognizes the structural opportunities in the wealth management sector, driven by the increasing trend of residents shifting their assets to financial products [5]. - Huatai Securities has enhanced its client service capabilities by optimizing customer segmentation and providing tailored financial solutions for various client groups, including high-net-worth individuals [5][6]. - The firm has developed a comprehensive asset allocation service system, offering a range of financial products and services to meet diverse client needs [5]. Group 3: International Expansion - Huatai Securities has prioritized international business as a strategic focus, expanding its global footprint through various initiatives, including establishing subsidiaries in key markets like the U.S., Singapore, and Japan [8][9]. - The company aims to create an integrated cross-border business model, enhancing its competitiveness in global markets and improving its service offerings [8][9]. - Huatai Securities has achieved significant milestones in international markets, including leading IPO projects in Hong Kong and the U.S., thereby strengthening its global market influence [8]. Group 4: Industry Position and Future Outlook - The article highlights the critical role of securities firms in connecting the real economy with capital markets, emphasizing the need for high-quality financial services to support economic transformation [4][11]. - Huatai Securities is positioned to leverage its capabilities in capital markets to foster innovation and resource allocation, contributing to the development of high-quality technology enterprises [11][12]. - The company is committed to adhering to the principles of the 14th Five-Year Plan, focusing on high-quality development and enhancing its service capabilities to support the construction of a financial powerhouse in China [11][12].

华泰证券(06886)发布公告，华泰证券股份有限公司2026年面向专业投资者公开发行次级债券(第一期)分 为两个品种，根据网下专业机构投资者询价结果，经发行人和主承销商协商一致，最终确定本期债券品 种一的票面利率为1.99%，品种二的票面利率为2.20%。 ...

智通财经APP讯，华泰证券(06886)发布公告，华泰证券股份有限公司2026年面向专业投资者公开发行次 级债券(第一期)分为两个品种，根据网下专业机构投资者询价结果，经发行人和主承销商协商一致，最 终确定本期债券品种一的票面利率为1.99%，品种二的票面利率为2.20%。 ...

根据《华泰证券股份有限公司2026年面向专业投资者公开发行次级债券(第一期)发行公告》，华泰证券 股份有限公司2026年面向专业投资者公开发行次级债券(第一期)(以下简称"本期债券")分为两个品种， 其中品种一期限为3年，票面利率询价区间为1.5%-2.5%；品种二期限为1816天，票面利率询价区间为 1.7%-2.7%。本期债券票面利率由发行人和主承销商根据网下利率询价结果在利率询价区间内协商确 定。 2026年1月20日，发行人和主承销商在网下向专业机构投资者进行了票面利率询价。根据网下专业机构 投资者询价结果，经发行人和主承销商协商一致，最终确定本期债券品种一的票面利率为1.99%，品种 二的票面利率为2.20%。 格隆汇1月20日丨华泰证券(06886.HK)公告，华泰证券股份有限公司(以下简称"发行人")面向专业投资者 公开发行总额不超过人民币200亿元(含200亿元)的次级公司债券已于2024年7月31日获中国证券监督管 理委员会出具的《关于同意华泰证券股份有限公司向专业投资者公开发行次级公司债券注册的批复》 (证监许可〔2024〕1109号)。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不對因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立之股份有限公司， 中文公司名稱為華泰證券股份有限公司，在香港以HTSC名義開展業務） （股份代號：6886） 海外監管公告 本公告乃根據上市規則第13.10B條規則作出。 茲載列本公司在上海證券交易所網站刊登之《華泰證券股份有限公司2026年面向 專業投資者公開發行次級債券（第一期）票面利率公告》，僅供參閱。 釋義 於本公告，除文義另有所指外，下列詞彙具有以下涵義。 「本公司」 指 於中華人民共和國以華泰證券股份有限公司的公司名 稱註冊成立的股份有限公司，於2007年12月7日由前身 華泰證券有限責任公司改制而成，在香港以「HTSC」 名義開展業務，根據公司條例第16部以中文獲准名稱 「華泰六八八六股份有限公司」及英文公司名稱「Huatai Securities Co., Ltd.」註冊為註冊非香港公司，其H股於 2015年6月1日在香港聯合交易所有限公司主板上市（股 票代碼：6 ...

智通财经APP讯，HTSC(06886)发布公告，华泰证券股份有限公司2021年面向专业投资者公开发行次级 债券(第一期)将于2026年1月29日本息兑付及摘牌。本期债券简称："21华泰C1"，本期债券票面利率(计 息年利率)为4.50%，每手本期债券兑付本金为人民币1000元，派发利息为人民币45.00元(含税)。 （原标题：HTSC(06886)："21华泰C1"将于1月29日本息兑付及摘牌） ...

Core Viewpoint - HTSC (06886) announced the public issuance of subordinated bonds aimed at professional investors, with a maturity date set for January 29, 2026, and a coupon rate of 4.50% [1] Group 1 - The bond is referred to as "21 Huatai C1" [1] - The principal amount for each bond is set at RMB 1,000, with an interest payment of RMB 45.00 (including tax) [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不對因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立之股份有限公司， 中文公司名稱為華泰證券股份有限公司，在香港以HTSC名義開展業務） （股份代號：6886） 海外監管公告 本公告乃根據上市規則第13.10B條規則作出。 於本公告，除文義另有所指外，下列詞彙具有以下涵義。 「本公司」 指 於中華人民共和國以華泰證券股份有限公司的公司名 稱註冊成立的股份有限公司，於2007年12月7日由前身 華泰證券有限責任公司改制而成，在香港以「HTSC」 名義開展業務，根據公司條例第16部以中文獲准名稱 「華泰六八八六股份有限公司」及英文公司名稱「Huatai Securities Co., Ltd.」註冊為註冊非香港公司，其H股於 2015年6月1日在香港聯合交易所有限公司主板上市（股 票代碼：6886），其A股於2010年2月26日在上海證券交 易所上市（股票代碼：601688），其全球存託憑證於2019 年6月在倫敦證券交易所上市（證券 ...

Core Viewpoint - Hualan Biological Engineering has intensified its strategy in AI-driven pharmaceuticals by expanding its AI Medical Expert Committee and electing new members, indicating a commitment to leveraging AI in drug development [1][2] Group 1: Company Developments - Hualan Biological announced the addition of Hu Tony Ye to its AI Medical Expert Committee, enhancing the committee's expertise with his extensive background in biomedical engineering and industry connections [2] - The company plans to invest 20 million yuan in Suzhou Kema Biotechnology, which is expected to benefit from the technological integration of its shareholders and Hualan's extensive client network [1][2] Group 2: Market Outlook - Huatai Securities forecasts a significant growth in the global AI-enabled drug development market, projecting an increase from $11.9 billion in 2023 to $74.6 billion by 2032, with a compound annual growth rate of 22.6% [3] - The report highlights that Hualan's core business is expected to maintain growth, particularly in its cartridge business, with revenue growth projected between 5% and 15% [3] Group 3: Financial Projections - Huatai Securities has raised its target price for Hualan from 39.46 yuan to 69.60 yuan, maintaining a "buy" rating based on the company's growth potential in AI pharmaceuticals and ongoing order fulfillment [4]

Core Viewpoint - Huatai Securities has issued a notice regarding the issuance of medium-term notes by its wholly-owned subsidiary, Huatai International Financial Holdings, under a $3 billion medium-term note program established in 2020, with a recent issuance of RMB 250 million [1] Group 1 - As of January 20, 2026, Huatai Securities' stock closed at RMB 23.26, up 1.88% from the previous trading day, with a total market capitalization of RMB 209.965 billion [1] - The stock opened at RMB 22.80, reached a high of RMB 23.40, and a low of RMB 22.80, with a trading volume of RMB 1.995 billion and a turnover rate of 1.18% [1] Group 2 - The recent issuance of RMB 250 million medium-term notes is guaranteed by Huatai International, with an actual guarantee balance of $2.118 billion [1] - As of the announcement date, the total amount of external guarantees provided by the company and its subsidiaries is RMB 48.752 billion, accounting for 25.43% of the latest audited net assets, all of which are guarantees for subsidiaries with no overdue guarantees [1]